Evelyne T. Lennette

California Pacific Medical Center Research Institute, San Francisco, California, United States

Are you Evelyne T. Lennette?

Claim your profile

Publications (2)7.66 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: The incidence of Epstein-Barr virus (EBV) infection and lymphoproliferative disorder (LPD) was determined in a pediatric liver transplant population consisting of 51 children treated with FK506 and 91 treated with cyclosporine. The incidence of symptomatic EBV infection was 21.9% (23 of 105 cases) in children < 5 yr old and 10.8% (4 of 37 cases) in children 5 to 17 yr old as compared with 2.7% (9 of 323 cases) in adults (P < 0.0001). In the under 5 yr old group on cyclosporine, the incidences of EBV infection and LPD were 9 of 68 (13.2%) and 2 of 68 children, (2.9%), respectively. In contrast, in children under 5 yr old group on FK506, the incidences of EBV infection and LPD in the FK506 group were 14 of 37 (37.8%) and 7 of 37 children (18.9%), respectively. The difference between these two groups was statistically significant (P < 0.02). There were no cases of LPD in the 5-17 yr-old children on either cyclosporine (n = 23) or FK506 (n = 14). The incidence of EBV infections in the 5 to 17 yr age group, 17.4% on cyclosporine and 0% on FK506, was less than for the younger children on FK506 (37.8%). A total of 39% (9 of 23) of children under 5 yr old who had symptomatic EBV infections developed LPD, and 44% (4 of 9) with LPD died. The higher incidence of EBV infections and LPD in the younger children treated with FK506 was probably related to a greater intensity of immunosuppression for patients on FK506 than those on cyclosporine.
    Transplantation 02/1995; 59(4):524-9. DOI:10.1097/00007890-199502270-00015 · 3.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Skin graft rejection and humoral alloantibody response (hemag-glutinins and cytotoxins) were observed in hyperimmunized mice (A/He to CBA strain combinations). Intact spleen cells or cell-free splenic preparations were used as immunizing agents. The initial use of adjuvant followed by 6 weekly i.v., i.p., or s.c. injections without adjuvant resulted in a slight but significant prolongation of the challenging skin graft survival in the presence of high antibody levels at the time of graft challenge. However, survival of the second challenging grafts in the same hyperimmunized recipients was much shorter, indicating that once the hyperimmunized recipients rejected the first challenging grafts, they became sensitized. Passive immunizations with a pooled immune serum or abdominal fluid resulted in a very slight prolongation, rather than accelerated rejection, of the challenging grafts. The possible roles of humoral antibodies in accelerated rejection (allograft sensitivity) and prolongation of graft survival (enhancement) are discussed.
    Transplantation 02/1995; 59(4):524-529. DOI:10.1097/00007890-199559040-00015 · 3.83 Impact Factor

Publication Stats

176 Citations
7.66 Total Impact Points

Top Journals


  • 1995
    • California Pacific Medical Center Research Institute
      • Department of Transplantation
      San Francisco, California, United States